Dr. John Cush RheumNow
1 year ago
DERM on RheumNow Podcast (September 2025)
Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more.
https://t.co/zZpheX1epS https://t.co/uOd9Gy0V2E
Dr. John Cush RheumNow
1 year ago
QD Clinic: Stick or twist (when not to change treatment
Dr. Richard Conway, Dublin, discusses a case about when not to change treatment, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/kUopZ1bpVi https://t.co/mt0tKcQzKQ
Dr. John Cush RheumNow
1 year ago
Assessing ILD in Rheumatology
Janet Pope, MD, shares practical insights on how rheumatologists should assess ILD in their patients. Sponsored By: Boehringer Ingelheim
https://t.co/Mxg9P50m7C
#ILD #Rheumatology https://t.co/aAuxbJBxBn
Dr. John Cush RheumNow
1 year ago
Scleroderma-associated Interstitial Lung Disease
Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/Dh7XpP6qhF
Dr. John Cush RheumNow
1 year ago
Panel of IPF assoc 8 biomarkers (eotaxin, Flt-3L, IL-8, MDC, MCP-1, MMP-2/7/9) tested in 2 RA-ILD cohorts (n 164). IPF multibiomarker scores higher in RA-ILF vs RA alone. Highest quartile had ~2 fold incr risk of prevalent & incident ILD https://t.co/vYg9iB4EtH https://t.co/5ZZx6gg7A4
Several cohort studies conducted in Asia, Europe and the Americas have evaluated the clinical significance of antineutrophil cytoplasmic antibodies (ANCA) when detected in patients with interstitial lung disease (ILD) as well as the types of ILD encountered in patients with microscopic polyangiitis (MPA) and their effect on the prognosis of MPA.
Dr. John Cush RheumNow
1 year ago
Big Fat FDA Pink Slip (9.19.2025)
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip.
https://t.co/Za39hxI8Qf https://t.co/yN4K9tOuTt
Dr. John Cush RheumNow
1 year ago
Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk
Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months.
Dr. John Cush RheumNow
1 year ago
Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/ZeI9z4Civa https://t.co/LCI6kZ1z0v
Dr. John Cush RheumNow
1 year ago
Did Hydroxychloroquine Reduce COVID-19 Mortality?
A multicenter study investigated the association between hydroxychloroquine (HCQ) dosage and COVID-19 mortality among hospitalized patients from multiple medical centers in China. The analysis focused on dose effects of HCQ on https://t.co/BuHoMDwpuP
Dr. John Cush RheumNow
1 year ago
Comparative Frequency of Systemic autoimmune rheumatic diseases (SARDs) in Australia:
- SLE 57.9 per 100K
- Lupus nephritis 11.2 per 100K
- SSc 25.6 per 100K
- ANCA-associated vasculitis 10.8 per million PYs https://t.co/cx9LvswQ2E https://t.co/ltcXCw23bI
A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs).
